South Korea faces one of the most significant demographic challenges in the world, leading to a massive government-backed push for accessible fertility treatments. The South Korea Fertility Drug Surgery Market is characterized by the rapid adoption of "Next-Gen" pharmaceuticals, including recombinant human follicle-stimulating hormones (rFSH) that offer more predictable ovarian responses.

Beyond drugs, the South Korean market is a leader in surgical innovation, particularly in the realm of "Ovarian Tissue Cryopreservation" and the surgical retrieval of sperm. The integration of AI-driven diagnostic imaging allows Korean surgeons to perform highly targeted hysteroscopies to clear uterine obstructions with minimal tissue trauma. As the government expands insurance coverage for multiple rounds of IVF and associated surgeries, the South Korean market is serving as a global laboratory for how intensive medical intervention can support a nation's reproductive health goals.